BI836845 Plus Enzalutamide in Castrate Resistant Prostate Cancer (CRPC)

NCT02204072 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

120

Enrollment

INDUSTRY

Sponsor class

Conditions

Prostatic Neoplasms, Castration-Resistant

Interventions

DRUG: BI 836845
DRUG: Enzalutamide
DRUG: Enzalutamide

Sponsor

Boehringer Ingelheim